Enjoy complimentary customisation on priority with our Enterprise License!
The musculoskeletal drugs market size is forecast to increase by USD 26.37 billion at a CAGR of 5.8% between 2023 and 2028. The market is experiencing significant growth due to several key trends and challenges. One of the primary drivers is the increasing prevalence of musculoskeletal pain, particularly among the aging population. Smooth muscle relaxants, such as Carisoprodol, Chlorzoxazone, Cyclobenzaprine, and Metaxalone, continue to be popular treatments for musculoskeletal pain. However, the high treatment costs associated with these prescription generic drugs have led to an increase in the adoption of over-the-counter (OTC) alternatives, such as Acetaminophen, as a more cost-effective solution. Another trend in the market is the adoption of artificial intelligence (AI) and machine learning (ML) technologies for diagnosing musculoskeletal conditions, which can help improve accuracy and reduce healthcare costs. Despite these trends, the high treatment costs remain a significant challenge for the market, and efforts are being made to develop more affordable treatment options to meet the growing demand.
Musculoskeletal disorders are a common health concern worldwide, affecting individuals of all ages. These conditions can manifest as muscle-related symptoms such as spasticity, spasms, and musculoskeletal pain. For those dealing with these symptoms, understanding the available treatment options is crucial. In this article, we will explore various aspects of the market, providing valuable information for those seeking relief at home. Stay informed about the latest developments in musculoskeletal drug treatments by attending community webinars. These educational events offer translated information on various topics, including prescription medications, over-the-counter (OTC) options, and alternative therapies.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The nonsteroidal anti inflammatory drugs segment is estimated to witness significant growth during the forecast period. Musculoskeletal disorders (MSDs) are a common health concern, causing pain, inflammation, and restricted mobility. Medications, particularly those in the market, play a significant role in managing these conditions. Among these, drugs like Methocarbamol, Orphenadrine, Baclofen, Dantrolene, Tizanidine, and Diazepam are commonly used.
Get a glance at the market share of various segments Download the PDF Sample
The nonsteroidal anti inflammatory drugs segment was the largest segment and was valued at USD 19.17 billion in 2018. These drugs function differently from Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which inhibit the production of prostaglandins, mediators of pain and inflammation. Methocarbamol, Orphenadrine, and Baclofen are muscle relaxants, while Dantrolene and Tizanidine are skeletal muscle relaxants and antispasmodics, respectively. Diazepam is a benzodiazepine, primarily used to manage anxiety and seizures. These drugs offer relief from various symptoms, including muscle spasms, pain, and anxiety. The choice of medication depends on the specific condition and its severity. Muscle relaxants are often used for short-term relief of muscle spasms and pain, while antispasmodics are used to treat conditions like spasticity. Benzodiazepines like Diazepam are used to manage anxiety and seizures. These drugs are available in various forms, including tablets, capsules, injectables, and extended-release formulations. Healthcare providers tailor treatment plans based on individual patient needs, considering factors like dosage, duration of action, and potential side effects. It is essential to follow the prescribed dosage and consult a healthcare professional for any concerns or questions.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 32% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Musculoskeletal disorders (MSDs) are a major health concern in North America, with significant numbers of cases reported in both the United States and Canada. In Canada, lost time injuries due to MSDs reached 10,211 in 2022, marking a 2.5% increase from the previous year. The high prevalence of MSDs can be attributed to several factors, including an aging population and rising obesity rates. In fact, obesity prevalence exceeded 20% in all US states and territories in 2023.
Furthermore, these statistics highlight the substantial impact of MSDs on workplace productivity, health, and overall quality of life. Commonly used drugs for treating MSDs include Paracetamol, Opioids such as Codeine, Capsaicin, and drugs that inhibit Prostaglandin synthesis. While these medications provide relief from pain and inflammation, they can also pose risks, particularly with long-term use and the potential for addiction. Therefore, proper management and monitoring of MSDs and their treatment are crucial to minimize adverse effects.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing geriatric population is notably driving market growth. The global market experiences significant growth due to the increasing elderly population. With the global population expanding, the number and percentage of older adults are rising rapidly. By 2050, the percentage of the world's population aged 60 and above is projected to almost double, climbing from 12% to 22%. This demographic shift is particularly noticeable in countries like China, India, and Indonesia, as well as in North American nations such as the US, Canada, and Mexico, where the elderly population is anticipated to quadruple by the end of this decade.
Furthermore, this demographic trend significantly impacts the demand for musculoskeletal drugs, as older adults are more prone to musculoskeletal conditions. To support this growing population, various resources are available. At home, individuals can find recipes for healthy meals that promote bone health through websites like MHA Kids. Community webinars offer translated information about musculoskeletal conditions and treatments, ensuring accessibility for all. Financial support is also available through bequests and donations to organizations that fund research and provide resources for those in need. Thus, such factors are driving the growth of the market during the forecast period.
Adoption of AI and ML for diagnosing musculoskeletal conditions is the key trend in the market. The market is experiencing significant advancements, with smooth muscle relaxants playing a crucial role in managing musculoskeletal pain. Over-the-counter (OTC) medications, such as Acetaminophen, are commonly used for mild to moderate pain relief. However, prescription drugs like Carisoprodol, Chlorzoxazone, Cyclobenzaprine, and Metaxalone are effective for treating muscle spasms and pain associated with musculoskeletal conditions. Artificial Intelligence (AI) and machine learning (ML) technologies are revolutionizing the diagnosis and treatment of musculoskeletal conditions.
Furthermore, these technologies offer numerous benefits, including noninvasive, real-time, cost-effective, and portable imaging solutions. AI algorithms have demonstrated impressive results in various applications, including fracture detection, bone age estimation, osteoarthritis diagnosis, and evaluating orthopedic implant-related pathologies. These advancements are transforming clinical practices by enabling rapid and dynamic assessments of musculoskeletal components. The integration of AI and ML in musculoskeletal care is expected to significantly enhance the accuracy and efficiency of diagnosing musculoskeletal conditions. These technologies enable healthcare professionals to make informed decisions, leading to improved patient outcomes and reduced healthcare costs. The musculoskeletal drugs market is expected to continue growing as new advancements and technologies emerge, offering innovative solutions for managing musculoskeletal conditions. Thus, such trends will shape the growth of the market during the forecast period.
High treatment costs associated with MSDs is the major challenge that affects the growth of the market. Musculoskeletal conditions, characterized by muscle-related symptoms such as spasticity, spasms, and skeletal muscle relaxants, account for a considerable portion of healthcare expenditure globally.
Furthermore, these conditions are a leading cause of disability and healthcare costs, with an average annual treatment cost per person estimated at around USD 7,800. However, this figure can vary significantly depending on the specific condition. The high treatment costs are primarily due to the extensive use of smart healthcare services across various specialties, necessitating the use of prescription medications such as antispasmodics, antispastics, and skeletal muscle relaxants. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers musculoskeletal medicine such as RINVOQ for the treatment of adults with moderate to severe rheumatoid arthritis.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Musculoskeletal drugs refer to medications used for managing various muscle-related symptoms and conditions, including spasticity, spasms, and musculoskeletal pain. These drugs include antispasmodics, antispasmodics, skeletal muscle relaxants, and smooth muscle relaxants. Individuals with conditions such as cerebral palsy, multiple sclerosis, and autoimmune-mediated or connective tissue disorders often require these medications. For those in need of financial support, community webinars, and translated information are available online. Many organizations offer prescription medications for musculoskeletal conditions through bequests and donations. Healthcare providers may prescribe these medications for managing symptoms related to joint disorders, muscle disorders, aging, and multimorbidity presentations.
Furthermore, over-the-counter (OTC) options like acetaminophen, carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, baclofen, dantrolene, tizanidine, diazepam, and others can be used for mild to moderate pain. Inflammation and prostaglandin synthesis are often targeted for pain relief. Holistic management, including pain clinics, can complement pharmacological management for chronic pain. However, it's essential to consider potential side effects, such as addiction with opioids, anxiety, seizures, and interaction with other medications. Capsaicin and nonsteroidal anti-inflammatory drugs (NSAIDs) like paracetamol and ibuprofen can be alternatives for managing pain without the risk of addiction.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
210 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.8% |
|
Market growth 2024-2028 |
USD 26.37 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.5 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 32% |
|
Key countries |
US, China, Germany, Japan, UK, India, France, Brazil, Canada, and Australia |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., Anika Therapeutics Inc., Astellas Pharma Inc., Bioventus LLC, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Kangstem Biotech Co Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi SA, Sorrento Therapeutics Inc., UCB SA, and Zimmer Biomet Holdings Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Drug Class
9 Market Segmentation by Distribution Channel
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
